Preliminary clinical trials have demonstrated that Locemia’s needle-free Glucagon Nasal Powder is as effective as the traditional injected form of glucagon in treating diabetes-related severe hypoglycemia. T1D Exchange scientists are presenting the research this week at the Advanced Technologies & Treatments for Diabetes international conference in Paris. Read the full press release from T1D Exchange.